1,652 top medical experts on Graft vs Host Disease across 48 countries and 41 U.S. states, including 1,605 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Graft vs Host Disease: The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft VS host reaction.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Immune System Diseases (1,465).
  4. Clinical Trials ClinicalTrials.gov : at least 708 including 43 Active, 284 Completed, 130 Recruiting
  5. Synonyms: Graft-Versus-Host Disease,  Homologous Wasting Disease,  Runt Disease


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Blazar, Bruce R   Pediatric Hematology-Oncology   Google Publications
    Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Relevant US NIH Grant Funding: $10,263,596 over the last 5 years
    Disclosed payments from biomedical company (KADMON PHARMACEUTICALS LLC) in 2021 for $3,610
    Subjects: Hematopoietic Stem Cell Transplantation; T-Lymphocytes, Regulatory; Bone Marrow Transplantation; T-Lymphocytes; Hematologic Neoplasms
    Categories: Immunology; Metabolism; Prevention & Control; Adverse Effects; Therapeutic Use; Therapy
    Advances in graft-versus-host disease biology and therapy. (2012)
    Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. (2015)

  2. Cutler, Corey S   Hematology & Oncology   ClinicalTrials.gov Google Publications
    Department of Stem Cell Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 66/100
    Disclosed payments in 2021 from 21 biomedical companies, totalling $41,746.57, including $10,000 from  Mallinckrodt Hospital Products Inc.
    Subjects: Hematopoietic Stem Cell Transplantation; Hematologic Neoplasms; Interleukin-2; T-Lymphocytes, Regulatory; Transplantation Conditioning
    Categories: Immunology; Therapy; Adverse Effects; Therapeutic Use; Drug Therapy; Methods
    National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. (2015)
    Interleukin-2 and regulatory T cells in graft-versus-host disease. (2011)

  3. Pavletic, Steven Zivko   Hematology & Oncology   ClinicalTrials.gov Google Publications
    Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports  Review 
    Relevant US NIH Grant Funding: $1,468,675 over the last 5 years
    Subjects: Hematopoietic Stem Cell Transplantation; Hematologic Neoplasms; Eye Diseases; Clinical Trials as Topic; Skin Diseases
    Categories: Therapy; Diagnosis; Adverse Effects; Metabolism; Pathology; Etiology
    National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. (2015)
    Risk factors for acute GVHD and survival after hematopoietic cell transplantation. (2012)

  4. Jagasia, Madan H   Hematology & Oncology   ClinicalTrials.gov Google Publications
    Vanderbilt-Ingram Cancer Center, Nashville, TN.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 73.2/100
    Subjects: Hematopoietic Stem Cell Transplantation; Skin Diseases; Hematologic Neoplasms; Immunosuppressive Agents; Transplantation Conditioning
    Categories: Therapeutic Use; Diagnosis; Therapy; Drug Therapy; Mortality; Methods
    National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. (2015)
    Risk factors for acute GVHD and survival after hematopoietic cell transplantation. (2012)

  5. Weisdorf, Daniel J   Hematology & Oncology   Google Publications
    Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports  Review 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 71/100
    Disclosed payments in 2021 from 3 biomedical companies, totalling $13,704, including $13,704 from  Incyte Corporation
    Subjects: Hematopoietic Stem Cell Transplantation; Hematologic Neoplasms; Bone Marrow Transplantation; Transplantation Conditioning; Cord Blood Stem Cell Transplantation
    Categories: Mortality; Adverse Effects; Methods; Therapy; Prevention & Control; Immunology
    National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. (2015)
    Risk factors for acute GVHD and survival after hematopoietic cell transplantation. (2012)

  6. Flowers, Mary Evelyn   Nephrology   Google Publications
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington. Top Hospital
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Review 
    Subjects: Hematopoietic Stem Cell Transplantation; Hematologic Neoplasms; Immunosuppressive Agents; Transplantation Conditioning; Cyclosporine
    Categories: Therapeutic Use; Therapy; Mortality; Adverse Effects; Diagnosis; Drug Therapy
    National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. (2015)
    Risk factors for acute GVHD and survival after hematopoietic cell transplantation. (2012)

  7. Antin, Joseph Harry   Medical Oncology   ClinicalTrials.gov Google Publications
    Department of Hematology/Oncology, Dana-Farber Cancer Institute, Boston, MA. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial  Review 
    Medical school: Js Weill Medical College, Cornell University (MD, 1978)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 66/100
    Disclosed payments in 2021 from 14 biomedical companies, totalling $16,125.01, including $7,600 from  Pharmacosmos Therapeutics Inc.
    Subjects: Hematopoietic Stem Cell Transplantation; Transplantation Conditioning; Hematologic Neoplasms; Interleukin-2; T-Lymphocytes, Regulatory
    Categories: Immunology; Therapy; Adverse Effects; Therapeutic Use; Prevention & Control; Etiology
    Interleukin-2 and regulatory T cells in graft-versus-host disease. (2011)
    Risk factors for acute GVHD and survival after hematopoietic cell transplantation. (2012)

  8. Pidala, Joseph A   Hematology & Oncology   ClinicalTrials.gov Google Publications
    H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports  Review 
    Relevant US NIH Grant Funding: $1,772,614 over the last 5 years
    Medicare MIPS (Merit-based Incentive Payment System) rating: 81/100
    Disclosed payments in 2021 from 4 biomedical companies, totalling $6,922.5, including $2,475 from  Deciphera Pharmaceuticals Inc.
    Subjects: Hematopoietic Stem Cell Transplantation; Hematologic Neoplasms; Sirolimus; Immunosuppressive Agents; Tacrolimus
    Categories: Therapeutic Use; Therapy; Mortality; Prevention & Control; Adverse Effects; Immunology
    Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). (2019)
    Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. (2015)

  9. Soiffer, Robert J   Medical Oncology   Google Publications
    Dana Farber Cancer Institute, Boston, MA.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Relevant US NIH Grant Funding: $6,719,468 over the last 5 years
    Medical school: New York University School of Medicine (MD, 1983)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 66/100
    Disclosed payments in 2021 from 4 biomedical companies, totalling $18,540, including $7,040 from  JAZZ PHARMACEUTICALS INC.
    Subjects: Hematopoietic Stem Cell Transplantation; T-Lymphocytes, Regulatory; Interleukin-2; Hematologic Neoplasms; Transplantation Conditioning
    Categories: Immunology; Therapeutic Use; Therapy; Methods; Drug Therapy; Administration & Dosage
    Interleukin-2 and regulatory T cells in graft-versus-host disease. (2011)
    Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. (2013)

  10. Ritz, Jerome   Hematology   Google Publications
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Relevant US NIH Grant Funding: $5,137,148 over the last 5 years
    Disclosed payments from biomedical company (Celgene Corporation) in 2021 for $2,260
    Subjects: Hematopoietic Stem Cell Transplantation; T-Lymphocytes, Regulatory; Interleukin-2; B-Lymphocytes; Hematologic Neoplasms
    Categories: Immunology; Therapy; Drug Therapy; Metabolism; Methods; Therapeutic Use
    Interleukin-2 and regulatory T cells in graft-versus-host disease. (2011)
    Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. (2013)

  11. Levine, John E   Pediatric Hematology-Oncology   ClinicalTrials.gov Google Publications
    Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Relevant US NIH Grant Funding: $1,057,442 over the last 5 years
    Medical school: Eastern Virginia Medical School (MD, 1989)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 72.4/100
    Disclosed payments from biomedical company (JAZZ PHARMACEUTICALS INC.) in 2021 for $6,360
    Subjects: Hematopoietic Stem Cell Transplantation; Transplantation Conditioning; Biomarkers; Bone Marrow Transplantation; Hematologic Neoplasms
    Categories: Blood; Metabolism; Adverse Effects; Mortality; Immunology; Therapeutic Use
    Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. (2014)
    EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. (2018)

  12. Ho, Vincent T   Medical Oncology   ClinicalTrials.gov Google Publications
    Dana Farber Cancer Institute, Boston, MA.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Relevant US NIH Grant Funding: $760,557 over the last 5 years
    Medicare MIPS (Merit-based Incentive Payment System) rating: 66/100
    Disclosed payments in 2021 from 5 biomedical companies, totalling $7,937.5, including $5,912.5 from  Alexion Pharmaceuticals, Inc.
    Subjects: Hematopoietic Stem Cell Transplantation; Hematologic Neoplasms; Interleukin-2; T-Lymphocytes, Regulatory; Transplantation Conditioning
    Categories: Immunology; Adverse Effects; Therapeutic Use; Methods; Therapy; Administration & Dosage
    Interleukin-2 and regulatory T cells in graft-versus-host disease. (2011)
    Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. (2015)

  13. Mohty, Mohamad   ClinicalTrials.gov Google Publications
    Service dHématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne University, and INSERM UMRs 938, Paris, France.
    Scientist  Highly Cited  Highly Published  Guideline  Clinical Trial  Review 
    Subjects: Hematopoietic Stem Cell Transplantation; Leukemia, Myeloid, Acute; Transplantation Conditioning; Antilymphocyte Serum; Precursor Cell Lymphoblastic Leukemia-Lymphoma
    Categories: Therapy; Therapeutic Use; Methods; Adverse Effects; Immunology; Prevention & Control
    Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. (2020)
    Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. (2020)

  14. Ferrara, James L M   Pediatric Hematology-Oncology   Google Publications
    Icahn School of Medicine, New York City, NY.
    Physician  Highly Cited  Highly Published  Clinical Trial  Review 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 72.4/100
    Disclosed payments in 2021 from 5 biomedical companies, totalling $7,260, including $7,260 from  Alexion Pharmaceuticals, Inc.
    Subjects: Hematopoietic Stem Cell Transplantation; Biomarkers; T-Lymphocytes; Transplantation Conditioning; Bone Marrow Transplantation
    Categories: Immunology; Blood; Metabolism; Mortality; Adverse Effects; Therapeutic Use
    Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. (2014)
    EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. (2018)

  15. Kitko, Carrie L   Pediatric Hematology-Oncology   Google Publications
    Division of Pediatric Hematology/Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee. Top Hospital
    Physician  Highly Cited  Clinical Trial 
    Medical school: Ohio State University College of Medicine (MD, 1999)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 73.2/100
    Disclosed payments in 2021 from 2 biomedical companies, totalling $4,755.22, including $4,650 from  Horizon Therapeutics plc
    Subjects: Hematopoietic Stem Cell Transplantation; Transplantation Conditioning; Immunosuppressive Agents; Hematologic Neoplasms; Antineoplastic Agents
    Categories: Therapy; Therapeutic Use; Mortality; Administration & Dosage; Adverse Effects; Blood
    National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. (2015)
    Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. (2015)

  16. Jacobsohn, David A   Pediatric Hematology-Oncology   ClinicalTrials.gov Google Publications
    Center for Cancer and Immunology Research, Childrens National Medical Center, Washington, DC, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Disclosed payments in 2021 from 5 biomedical companies, totalling $5,609.85, including $5,300 from  SANOFI US SERVICES INC.
    Subjects: Hematopoietic Stem Cell Transplantation; Hematologic Neoplasms; Clinical Trials as Topic; Severity of Illness Index; Bone Marrow Transplantation
    Categories: Mortality; Diagnosis; Adverse Effects; Therapy; Physiopathology; Methods
    National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. (2015)
    Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). (2019)

  17. Hill, Geoffrey R   Hematology   Google Publications
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Relevant US NIH Grant Funding: $3,247,548 over the last 5 years
    Medicare MIPS (Merit-based Incentive Payment System) rating: 72/100
    Subjects: Bone Marrow Transplantation; Hematopoietic Stem Cell Transplantation; Dendritic Cells; T-Lymphocytes, Regulatory; Graft vs Leukemia Effect
    Categories: Immunology; Metabolism; Adverse Effects; Etiology; Pathology; Pharmacology
    Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. (2017)
    Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. (2014)

  18. Zeiser, Robert   ClinicalTrials.gov Google Publications
    Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
    Scientist  Highly Cited  Highly Published  Guideline  Clinical Trial 
    Subjects: Hematopoietic Stem Cell Transplantation; T-Lymphocytes; MicroRNAs; Myeloid Cells; Pyrazoles
    Categories: Immunology; Metabolism; Therapeutic Use; Adverse Effects; Drug Therapy; Genetics
    Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. (2020)
    Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. (2020)

  19. Greinix, Hildegard Theresia     ClinicalTrials.gov Google Publications
    Clinical Division of Hematology, Medical University of Graz, Graz, Austria.
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports  Review 
    Subjects: Hematopoietic Stem Cell Transplantation; Photopheresis; Skin Diseases; Hematologic Neoplasms; Transplantation Conditioning
    Categories: Adverse Effects; Therapy; Diagnosis; Etiology; Immunology; Metabolism
    National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. (2015)
    Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. (2020)

  20. Koreth, John   Hematology & Oncology   ClinicalTrials.gov Google Publications
    Dana-Farber Cancer Institute. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medical school: Other (MD, 1993)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 66/100
    Disclosed payments in 2021 from 2 biomedical companies, totalling $2,792.5, including $2,292.5 from  Regeneron Pharmaceuticals, Inc.
    Subjects: Hematopoietic Stem Cell Transplantation; T-Lymphocytes, Regulatory; Interleukin-2; Hematologic Neoplasms; Transplantation Conditioning
    Categories: Immunology; Therapeutic Use; Drug Therapy; Therapy; Prevention & Control; Administration & Dosage
    Interleukin-2 and regulatory T cells in graft-versus-host disease. (2011)
    Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). (2019)

Note:
  1. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);